In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the mechanism of action and clinical rationale for the use of immune checkpoint inhibitors in patients with bladder cancer.
In this downloadable slideset, Matthew I. Milowsky, MD, discusses the current neoadjuvant and adjuvant treatment landscape in bladder cancer and highlights ongoing trials with immune checkpoint inhibitors in this setting.
In this downloadable slideset, Jean Hoffman-Censits, MD, discusses the optimal use of immune checkpoint inhibitors for patients with treatment-naïve advanced bladder cancer.
In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the data on recent approvals for immune checkpoint inhibitors for patients with advanced bladder cancer who have progressed on previous therapy.
In this downloadable slideset, Andrea B. Apolo, MD, addresses the management of adverse events associated with immune checkpoint inhibitors and highlights new data for treatment options after immune checkpoint inhibitors for optimal outcomes in patients with advanced bladder cancer.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.